Drug Trial Radar · NCT03020030
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
560
Actual
Start
Mar 3, 2017
Primary completion
Nov 30, 2026
Study completion Nov 2034
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Servier
- First posted
- Jan 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells. ALL is always fatal if it is not treated. With current treatments, most children and adolescents with this disease will be cured. The standard treatment for ALL involves about 2 years of chemotherapy. The drugs that are used, and the doses of the drugs, are similar but not identical for all children and adolescents with ALL. Some children and adolescents receive stronger treatment, especially during the first several months. A number of factors are used to decide how strong the treatment should be to give the best chance for cure. These factors are called "risk factors". This trial is studying the use of a new, updated set of risk factors to decide how strong the treatment will be. The study also will test a new way of dosing a chemotherapy drug called pegaspargase (which is part of the standard treatment for ALL) based on checking levels of the drug in the blood and adjusting the dose based on the levels.
Conditions
- Acute Lymphoblastic Leukemia, Pediatric
Interventions
PegaspargaseDrug
Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
Erwinia asparaginaseDrug
Only for patients with Pegaspargase allergy or silent inactivation.
CyclophosphamideDrug
Standard of Care
CYTARABINEDrug
Standard of Care
DASATINIBDrug
Standard of Care
DEXAMETHASONEDrug
Standard of Care
DexrazoxaneDrug
Standard of Care
DoxorubicinDrug
Standard of Care
ETOPOSIDEDrug
Standard of Care
HYDROCORTISONEDrug
Standard of Care
LEUCOVORIN CALCIUMDrug
Standard of Care
MERCAPTOPURINEDrug
Standard of Care
METHOTREXATEDrug
Standard of Care
NELARABINEDrug
Standard of Care
VincristineDrug
Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Remission RateTime frame: After 1 month of treatment (Induction IA) for all participants, assessed at the end of first month of treatment in all participants through study completion (expected to take 4-5 years to accrue)
- Event-Free SurvivalTime frame: From registration to the time of induction failure, relapse, death, or second malignancy, whichever came first, assessed up to 60 months.
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian
New York, New York
Montefiore Medical Center
The Bronx, New York
Hasbro Children's Hospital / Rhode Island Hospital
Providence, Rhode Island
Hospital Sainte Justine, University of Montreal
Montreal, Quebec, Canada
Centre Hospitalier U. de Quebec
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.